Pharmacological and behavioral profile of ACP-103, a novel 5-HT 2A receptor inverse agonist
暂无分享,去创建一个
Robert I. Davis | M. Geyer | D. Weiner | M. Brann | F. Piu | S. Powell | J. Lameh | E. Burstein | I. Veinbergs | M. Thygesen | Thomas Son | S. C. Harvey | L. Gardell | K. Vanover | A. Tredici | N. Schlienger | C. Andersson | M. Makhay | R. Thomas | H. Schiffer | Ott | A. Uldam | Bo Tolf | T. Son | B. Tolf
[1] C. Halldin,et al. High 5-HT2 receptor occupancy in clozapine treated patients demonstrated by PET , 2005, Psychopharmacology.
[2] H. Meltzer,et al. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. , 2004, The American journal of psychiatry.
[3] M. Caron,et al. RNA Editing Induces Variation in Desensitization and Trafficking of 5-Hydroxytryptamine 2c Receptor Isoforms* , 2004, Journal of Biological Chemistry.
[4] U. Hacksell,et al. Pharmacological Characterization of AC-90179: a Selective 5-HT 2A Receptor Inverse Agonist , 2004 .
[5] M. Geyer,et al. Dopaminergic stimulation disrupts sensorimotor gating in the rat , 2004, Psychopharmacology.
[6] Psychosis of Parkinson's disease: serotonin 2A receptor inverse agonists as potential therapeutics. , 2003, Current opinion in investigational drugs.
[7] M. Stryker,et al. Sleep and Sleep Homeostasis in Mice Lacking the 5-HT2c Receptor , 2002, Neuropsychopharmacology.
[8] J. Friedman,et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease , 2002, Biological Psychiatry.
[9] M A Geyer,et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. , 2001, The Journal of pharmacology and experimental therapeutics.
[10] E. Esposito,et al. Role of 5-HT(2C) receptors in the control of central dopamine function. , 2001, Trends in pharmacological sciences.
[11] M. Teitler,et al. Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[12] J. Wettstein,et al. Selectivity of action of typical and atypical antipsychotic drugs as antagonists of the behavioral effects of 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) , 1999, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[13] A. Carlsson,et al. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice , 1999, Journal of Neural Transmission.
[14] K. Uryu,et al. Pattern of expression of the serotonin2C receptor messenger RNA in the basal ganglia of adult rats , 1997, The Journal of comparative neurology.
[15] R. Emeson,et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing , 1997, Nature.
[16] J. Kehne,et al. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. , 1996, The Journal of pharmacology and experimental therapeutics.
[17] R. Eglen,et al. The pharmacology and distribution of human 5‐hydroxytryptamine2B (5‐HT2b) receptor gene products: comparison with 5‐HT2a and 5‐HT2c receptors , 1995, British journal of pharmacology.
[18] H. Meltzer,et al. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease: A high potency effect of clozapine , 1995 .
[19] B. Roth,et al. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. , 1992, The Journal of pharmacology and experimental therapeutics.
[20] F. Colpaert,et al. Binding of typical and atypical antipsychotics to 5-HT1C and 5-HT2 sites: clozapine potently interacts with 5-HT1C sites. , 1990, European journal of pharmacology.
[21] N. Swerdlow,et al. Startle response models of sensorimotor gating and habituation deficits in schizophrenia , 1990, Brain Research Bulletin.
[22] H. Meltzer,et al. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. , 1989, The Journal of pharmacology and experimental therapeutics.
[23] J. Leysen,et al. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. , 1985, Molecular pharmacology.
[24] W. Freed,et al. Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice , 1984, Neuropharmacology.
[25] M. Geyer,et al. Prestimulus effects on human startle reflex in normals and schizophrenics. , 1978, Psychophysiology.
[26] J. Leysen,et al. A serotonergic component of neuroleptic receptors. , 1977, Archives internationales de pharmacodynamie et de therapie.
[27] S. Snyder,et al. The dopamine hypothesis of schizophrenia: focus on the dopamine receptor. , 1976, The American journal of psychiatry.